⚠ Tool for educational and informational purposes only — not investment advice or a recommendation to buy or sell. Investing carries risk of capital loss. Read the full disclaimer.
MRK — Merck & Co., Inc.
Last scan (Sept. 15, 2026): price $144.85, RSI 52.00, relative volume 0.67x, MACD ⚪ No, score 35.59.
It's in a bullish underlying trend (above its 200-day average), with an RSI of 52.0 in a neutral zone. Neither the MACD nor a range breakout gives a technical entry signal right now. Relative volume of 0.67x is below normal — little interest today. The analysts' average target price implies a modest +5.6% upside. With a PEG of 2.63, the price already bakes in high growth expectations.
Price chart
MRK
Price: $146.75 · RSI (14): 57.73 · Rel. volume: 3.16x · Breakout: No
- Current price: ($146.75) — solid white line — the latest available closing price.
- Target price: ($152.96) — dashed green line — average 12-month target price from analysts covering the stock.
- Quarter low: ($142.32) — dotted orange line — the lowest price over the last ~3 months, as a recent support reference.
You can zoom by dragging a rectangle over the chart, or with your mouse wheel. Double-click to reset the view.
What analysts say
MRK
Merck & Co., Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo,…
- Buy 20
- Hold 8
- Sell 0
Average target price: $152.96 (+4.1% vs. current price) · range $105.0 – $186.0
Healthy Moderate Attention No data
Total market value of the company (price × shares outstanding).
P/E (trailing): compares the stock's price with its earnings per share over the last 12 months — how many times that earning is being paid for.
High: the market is paying a premium, usually because it expects strong growth. If the company doesn't deliver, the price could correct sharply.
P/E (forward): same as P/E, but using analysts' estimated earnings per share for the next year.
Same as P/E, using estimated future earnings.
PEG: the P/E divided by the expected earnings growth rate — relates how expensive the stock is to how fast it's expected to grow.
Above 2: even accounting for expected growth, the price looks expensive.
Debt/Equity: how much debt the company carries per dollar of shareholder equity — measures how leveraged the balance sheet is.
Moderate leverage, normal in many industries.
Net margin: what percentage of each dollar of revenue ends up as net profit, after all costs.
Low margin: the business has little cushion if costs rise.
Dividend: what percentage of the stock's price is paid out in cash to shareholders each year.
Pays out a portion of its earnings as cash to shareholders on a recurring basis.
Beta: how volatile the stock is compared to the overall market (S&P 500 = 1.0).
Less volatile than the overall market (S&P 500 = 1.0).
General reference ranges, do not vary by sector. Third-party data; may be incomplete. Not investment advice.
💰 Financial Statements (last 3 quarters)
💰 Financial Statements (last 3 quarters)
What this chart shows
- Japanese candlesticks: green when the period's close is higher than its open, red when it's lower.
- Volume: bars colored the same as the candle for that period.
- RSI (14): bottom line with reference levels at 70 (overbought) and 30 (oversold) — the same indicator the daily scanner uses.
- Dotted line on top: the high of the last 20 periods, the same reference the scanner uses to detect breakouts.
Third-party market data, for informational purposes. Not investment advice — read the disclaimer.